Table 4.

Cox multivariable analysis.

Variable	Model 1: baseline coexisting conditions		Model 2: baseline coexisting conditions, cardiac biomarker elevation and clinical severity
	HR (95% CI)	P	HR (95% CI)	P
Age per 1-year increase	1.07 (1.06 − 1.08)	< 0.001	1.05 (1.03 − 1.06)	< 0.001
Male sex	1.45 (1.12 − 1.86)	0.005	1.69 (1.11 − 2.57)	0.01
Obese	1.16 (0.87 − 1.55)	0.32	1.05 (0.67 − 1.65)	0.83
Hypertension	1.00 (0.74 − 1.36)	0.99	0.94 (0.58 − 1.54)	0.82
Diabetes	1.44 (1.09 − 1.89)	0.009	1.72 (1.12 − 2.63)	0.01
Dyslipidaemia	1.12 (0.86 − 1.46)	0.41	1.10 (0.73 − 1.66)	0.65
Chronic kidney failure	1.61 (1.22 − 2.11)	< 0.001	1.57 (1.02 − 2.41)	0.04
Chronic respiratory failure	1.31 (0.75 − 2.29)	0.35	1.64 (0.74 − 3.62)	0.22
Coronary artery disease	1.02 (0.74 − 1.40)	0.90	0.76 (0.47 − 1.23)	0.26
Chronic heart failure	1.37 (1.01 − 1.84)	0.04	1.21 (0.76 − 1.92)	0.43
Previous stroke	0.94 (0.67 − 1.31)	0.70	0.77 (0.45 − 1.31)	0.33
Elevated troponina	−	−	1.66 (1.11 − 2.49)	0.01
Elevated BNP or NT − pro-BNPb	−	−	1.69 (1.00 − 2.86)	0.049
qSOFA ≥ 2	−	−	1.71 (1.12 − 2.60)	0.01

BNP: B-type natriuretic peptide; CI: confidence interval; HR: hazard ratio; NT − pro-BNP, N-terminal pro-B-type natriuretic peptide; qSOFA: quick Sequential Organ Failure Assessment.

^aAbove each centre threshold.

^bBNP > 50 pg/mL or NT − pro-BNP > 300 pg/mL.